WuXi Biologics (Cayman) Inc.

2269

KYG970081173

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
13.48 ^HKD	+5.81%		+6.81%	-54.46%

Apr. 01	Wuxi Biologics Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer	CI
Mar. 27	WuXi Biologics' 2023 Profit Falls 23% Despite Revenue Jump	MT

WuXi Biologics Inc.(SEHK:2269) dropped from S&P International 700

March 17, 2024

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

Latest news about WuXi Biologics (Cayman) Inc.

Wuxi Biologics Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer	Apr. 01	CI
WuXi Biologics' 2023 Profit Falls 23% Despite Revenue Jump	Mar. 27	MT
WuXi Biologics 2023 Net Profit Fell on Higher Expenses, Impairment Losses	Mar. 26	DJ
WuXi Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Hong Kong Shares Slip Amid Downbeat Earnings, Cautious Trade	Mar. 19	MT
WuXi AppTec's Shares Fall After Downbeat Guidance	Mar. 19	DJ
WuXi AppTec's Net Profit Jumps, Reiterates It Doesn't Pose Security Threat	Mar. 18	DJ
WuXi Biologics Inc.(SEHK:2269) dropped from S&P International 700	Mar. 17	CI
WuXi Biologics Inc.(SEHK:2269) dropped from S&P Global 1200	Mar. 17	CI
Hong Kong Shares Drop as PBoC Keeps Key Policy Rate Unchanged	Mar. 15	MT
WuXi Shares Fall as Washington Lobbying Group Cuts Ties	Mar. 14	DJ
China stocks steady, helped by biotech rally; Wuxi Apptec drags Hong Kong shares	Mar. 14	RE
Biotech trade association to split with China's WuXi AppTec	Mar. 13	RE
Huanghe Whirlwind Names Chairman, Vice Chairman	Mar. 12	MT
WuXi AppTec 'Strongly Disagrees' With US Draft Bill Amid Share Slump	Mar. 07	MT
WuXi Biologics Refutes Ties With WuXi AppTec Amid Stock Slump	Mar. 07	MT
Hong Kong Shares Drop as US Bill Fixes On Chinese Biotech Firms	Mar. 07	MT
WuXi Companies' Shares Fall Amid Renewed U.S. Sanction Concerns	Mar. 07	DJ
Hong Kong Shares Advance as Traders Eye Earnings Data; JD.com Rises 8%	Mar. 06	MT
WuXi Companies' Shares Rise on Receding Worries About Potential U.S. Sanctions	Mar. 04	DJ
Nomura Adjusts Wuxi Biologics' Price Target to HK$53.65 From HK$58.44, Keeps at Buy	Mar. 01	MT
China stocks set to snap nine-session winning run, HK shares also down	Feb. 25	RE
Hong Kong stocks rise, China markets reopen next week after Lunar New Year break	Feb. 15	RE
WuXi Shares Hit by U.S. Committee Seeking Inquiry, Blacklisting	Feb. 14	DJ
Wuxi Biologics Says It Is Not a Wuxi AppTec Subsidiary Amid US Security Risk Probe	Feb. 13	MT

Chart WuXi Biologics (Cayman) Inc.

Duration

Period

More charts

WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing services of biologics. Through fully-integrated biologics Contract Research, Development and Manufacturing Organization (CRDMO), the Company provides one-stop end-to-end biologics services. Biologics development process stages include pre-IND (drug discovery and pre-clinical development), early-phase (phases I & II) clinical development, late-phase (phase III) clinical development and commercial manufacturing. The Company also offers end-to-end vaccine CRDMO services, including vaccine discovery and development, scale-up commercial manufacturing and global distribution. The Company has WuXiBody bispecific antibody platform, SDArBodY multispecific antibody platform, WuXia cell line development platform, WuXiUP continuous manufacturing platform and mRNA vaccine platform. The Company mainly operates its businesses in the domestic and overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-08-18 - Q2 2024 Earnings Release (Projected)

Related indices

HONG KONG HANG SENG

More about the company

Income Statement Evolution

More financial data

Ratings for WuXi Biologics (Cayman) Inc.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.48 CNY

Average target price

26.4 CNY

Spread / Average Target

+111.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
WUXI BIOLOGICS (CAYMAN) INC.	-54.46%	7.17B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs

WuXi Biologics (Cayman) Inc.

Equities

2269

KYG970081173

Biotechnology & Medical Research

WuXi Biologics Inc.(SEHK:2269) dropped from S&P International 700

Latest news about WuXi Biologics (Cayman) Inc.

Chart WuXi Biologics (Cayman) Inc.

Company Profile

Income Statement Evolution

Ratings for WuXi Biologics (Cayman) Inc.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs